MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

NCT06648434 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Cancer of the Pancreas

Interventions

DRUG: Zunsemetinib
DRUG: mFOLFIRINOX

Sponsor

Washington University School of Medicine

Collaborators

National Cancer Institute (NCI)
Aclaris Therapeutics, Inc.